
样式: 排序: IF: - GO 导出 标记为已读
-
Under Pressure: The Prognostic Role of Blood Pressure in Heart Failure With Preserved Ejection Fraction J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Stefano Masi, Hermann Dalpiaz, Gianluigi Savarese
Section snippets Funding Support and Author DisclosuresDr Masi has received honoraria for lecturing, consulting, and editorial activity from Servier outside the current work. Dr Savarese has received personal fees from Roche, Abbott, Edwards Lifesciences, Medtronic, TEVA, Menarini, INTAS, GETZ, CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, and Pharmacosmos; and has
-
Setting Benchmarks for Long-Term Success of Surgical Mitral Valve Repair in Reference Centers J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Makoto Mori, Arnar Geirsson
Section snippets Comparing Contemporary and Historical DataOne of the salient findings of this study is the extraordinarily low 30-day mortality rate of 0.48%, which further drops to 0.21% for isolated MV repair cases. Their cohort was predominantly low risk, with EuroSCORE II of 0.9%. The outcomes reported by Del Forno et al5 compare favorably to the operative mortality of 1.16% for isolated degenerative
-
Long-Term Outcomes of Contemporary Surgical Repair for Degenerative Mitral Regurgitation J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Benedetto Del Forno, Guido Ascione, Davide Carino, Mariangela D’Ovidio, Elisabetta Lapenna, Alessandro Verzini, Paolo Denti, Andrea Blasio, Nicolò Azzola Guicciardi, Anna Mara Scandroglio, Fabrizio Monaco, Eustachio Agricola, Marina Davoli, Giorgia Duranti, Giovanni Baglio, Enrico Coscioni, Alessandro Castiglioni, Ottavio Alfieri, Michele De Bonis, Francesco Maisano
-
Redefining Outcomes in Pediatric Cardiovascular Research: The Promise of Days Alive Out of Health Care J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Emily M. Bucholz, John M. Costello
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Incorporating the Totality of Ischemic and Hemorrhagic Events: The Case of the AUGUSTUS Trial J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Behnood Bikdeli, Dominick J. Angiolillo, Marco Valgimigli
Section snippets Funding Support and Author DisclosuresDr Bikdeli has served as the Associate Editor for JACC; outside of the submitted work, he has been supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814), the Scott Schoen and Nancy Adams IGNITE Award, the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women’s
-
Unlocking Therapeutic Potential for Cardiac Remodeling in Obesity-Related HFpEF: Lessons From the SUMMIT CMR Substudy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Khurram Nasir, Carlos E. Rochitte
Section snippets Unveiling the Cardiac Remodeling and Paracardiac Fat Reduction Impact of Tirzepatide: Insights from the SUMMIT CMR SubstudyEnter the SUMMIT CMR substudy published in this issue of JACC,5 which goes a step further by employing advanced cardiac magnetic resonance (CMR) imaging to provide in-depth insights into potential mechanisms underlying these clinical benefits. By assessing reductions
-
Early Aortic Valve Replacement for Asymptomatic Severe Aortic Stenosis: New Treatment Paradigms J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Yousif Ahmad, Rohin K. Reddy, James P. Howard
Section snippets Funding Support and Author DisclosuresDr Ahmad is a consultant for Cardiovascular Systems Inc and Shockwave; and serves on the Medical Advisory Board of Boston Scientific. Dr Reddy is funded by the Nuffield Department of Population Health, University of Oxford. Dr Howard is funded by the British Heart Foundation (FS/ICRF/22/26039).
-
Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Manasi Tannu, Renato D. Lopes, Daniel M. Wojdyla, Shaun G. Goodman, Ronald Aronson, Roxana Mehran, Christopher B. Granger, Stephan Windecker, John H. Alexander, W. Schuyler Jones
-
Days Alive Out of Health Care: A Novel Measure of Health Status After Congenital Heart Surgery J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-05 Sarah Crook, Chantal M. Sanchez, Kacie Dragan, Joyce L. Woo, Pengfei Jiang, Matthew Neidell, Brett R. Anderson
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03
Section snippets Advancing Prevention: Insights From JACC's Focus Issue433Harlan M. Krumholz Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study 436Philip Joseph, Álvaro Avezum, Chinthanie Ramasundarahettige, Prem K. Mony, Rita Yusuf, Khawar Kazmi, Andrzej Szuba, Patricio Lopez-Jaramillo, Maria Luz Diaz, Afzal Hussein Yusufali, Sadi Gulec, Roya
-
Advancing Prevention: Insights From JACC's Focus Issue J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Harlan M. Krumholz
Section snippets The Current Landscape: Opportunities and Implementation GapsThe landmark PURE study by Joseph et al1 reveals that in 17 countries, particularly in low- and middle-income regions, fewer than one-half of eligible patients receive essential secondary prevention medications. This implementation gap persists despite these interventions being inexpensive and readily available. The editorial
-
Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Philip Joseph, Álvaro Avezum, Chinthanie Ramasundarahettige, Prem K. Mony, Rita Yusuf, Khawar Kazmi, Andrzej Szuba, Patricio Lopez-Jaramillo, Maria Luz Diaz, Afzal Hussein Yusufali, Sadi Gulec, Roya Kelishadi, Li Wei, Jephat Chifamba, Fernando Lanas, Thandi Puoane, Ambigga Krishnapillai, Sumathy Rangarajan, Salim Yusuf, Lennon Gwaunza
-
PURE Evidence in Plain Sight: The Highs, Lows, and Gaps in Secondary Cardiovascular Prevention J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Abhishek Chaturvedi, Dorairaj Prabhakaran
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Making Secondary Prevention the Primary Focus for Cardiovascular Disease Control J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Oyere K. Onuma
Section snippets Funding Support and Author DisclosuresThe author has reported that he has no relationships relevant to the contents of this paper to disclose.
-
Does the Mechanism of Weight Loss Matter for Cardiovascular Protection? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Peder Langeland Myhre, Muthiah Vaduganathan
Section snippets Funding Support and Author DisclosuresDr Myhre has served on advisory boards and/or received speaker fees from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Novo Nordisk, Pharmacosmos, Roche, Sanofi, US2.ai, and Vifor. Dr Vaduganathan has received research grant support, served on advisory boards, or had speaker engagements with American Regent
-
Long-Term Lipid Lowering With Evolocumab in Older Individuals J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Samer Al Said, Michelle L. O’Donoghue, Xinhui Ran, Sabina A. Murphy, Dan Atar, Anthony Keech, Jose H. Flores-Arredondo, Bei Wang, Marc S. Sabatine, Robert P. Giugliano
-
Evolocumab in Older Individuals: Expanding the Age Horizon J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Kalyani Dhar, Jeffrey Berger, Jonathan Newman, Arthur Schwartzbard, Astrid Carolina Jara Pernia, Howard S. Weintraub
Section snippets Funding Support and Author DisclosuresDr Weintraub has received research funding for OCEAN, HORIZON trial, and ACCLAIM trial. Dr Newman has received grants from the National Institutes of Health. Dr Berger discloses a relationship with Janssen and discloses financial information from the National Institutes of Health/National Heart, Lung, and Blood Institute and the American Heart
-
Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Danish Iltaf Satti, Jeffrey Shi Kai Chan, Reed Mszar, Adhya Mehta, Yaa Adoma Kwapong, Raymond Ngai Chiu Chan, Olayinka Agboola, Erica S. Spatz, Jared A. Spitz, Khurram Nasir, Zulqarnain Javed, Jason A. Bonomo, Garima Sharma
-
Altering Adverse Social Determinants of Cardiovascular Health in Sexual Minorities J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Caroline Ong, Billy A. Caceres
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Amara Yad Image: Cardiac Fibrous Skeleton J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-02-03 Kalyanam Shivkumar
Section snippets Funding Support and Author DisclosuresThis work was supported by National Institutes of Health grants OT2OD023848 and P01 HL164311 to Dr Shivkumar and the UCLA Amara-Yad Project. Dr Shivkumar is a consultant to Nference and Anumana.
-
Empowering the Profession: The ACC’s Commitment to Cutting-Edge Clinical Guidance J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-30 Cathleen Biga, Ana Barac, Nicole Bhave
No Abstract
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27
Section snippets A Contemporary Picture of Coagulase-Negative Staphylococcal Endocarditis: A Nationwide GAMES Cohort Study 305Clara Palom-Grau, Guillermo Cuervo, Patricia Muñoz, Mercedes Marín Arriaza, Manuel Martínez-Sellés, Víctor González-Ramallo, Arístides de Alarcón, Manuel Poyato-Borrego, Raquel Rodríguez-García, M. Ángeles Rodríguez-Esteban, M. Carmen Fariñas, Claudia González-Rico, Miguel Ángel
-
Transforming Publishing: Your Paper, Your Way at JACC J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Harlan M. Krumholz
Section snippets The Central Tenets of YPYWOur YPYW policy is simple: authors should submit their manuscripts in whatever formatting style they find easiest and clearest. Initial submissions are evaluated for content, not formatting requirements. Our key principles include the following: 1.Focus on Content: The quality of the research, clarity of the message, and significance of the findings are our
-
Amara Yad Image: The Mitral Valve, Aortic Root, and Aortomitral Continuity J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Kalyanam Shivkumar
Section snippets Funding Support and Author DisclosuresThis work was supported by National Institutes of Health grants OT2OD023848 and P01 HL164311 to Dr Shivkumar and the UCLA Amara-Yad Project. Dr Shivkumar is a consultant to Nference and Anumana.
-
Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Chris J. Packard, Jan Borén, M. John Chapman
No Abstract
-
Reply: Plasma Triglyceride Reduction and Cardiovascular Risk in ODYSSEY Outcomes Trial: Interpret With Caution J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Doron Zahger, Gregory G. Schwartz, Michael Szarek, Sergio Fazio, P. Gabriel Steg
No Abstract
-
What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 John E. Madias
No Abstract
-
Reply: What Is the Diagnostic and Prognostic Value of the Electrocardiographic QRS Attenuation in Myocarditis? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Benedikt Bernhard, Christoph Gräni
No Abstract
-
Expanding the Dialogue on Atrial Fibrillation in the United States J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Connor G. Oltman, Taehyung P. Kim, James W.Y. Lee, John D. Lupu, Issam D. Moussa
No Abstract
-
Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Anastasios Apostolos, Maria Drakopoulou, Konstantinos Tsioufis, Konstantinos Toutouzas
No Abstract
-
Reply: Recurrent Ischemic Stroke After PFO Closure: Unconsidered Low RoPE Score and Thrombophilia J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-27 Kasper Bonnesen, Asger Andersen, Claus Ziegler Simonsen, Jens Erik Nielsen-Kudsk, Morten Schmidt
No Abstract
-
Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40-75 Years J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-25 Michael E. Bowdish, J. Hunter Mehaffey, Shu-Ching Chang, Patrick O’Gara, Michael J. Mack, Andrew Goldstone, Joanna Chikwe, A. Marc Gillinov, Changfu Wu, Greg Fontana, Joseph Bavaria, Chris Malaisrie, Tsuyoshi Kaneko, Ibrahim Sultan, Moritz W. von Ballmoos, Kathrine Harrington, Jeffrey Jacobs, Vinod Thourani, Wilson Szeto, Joseph Sabik, Vinay Badhwar
BackgroundThe choice of bioprosthetic or mechanical surgical aortic valve replacement (AVR) should balance individual valve durability with the potential liabilities of oral anticoagulation. ObjectiveTo inform clinical practice, this study sought to evaluate contemporary, real-world, long-term AVR outcomes from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS-ACSD). MethodsAll patients
-
Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-22 Richard K. Cheng, Douglas Leedy, Frederick L. Ruberg
Section snippets Funding Support and Author DisclosuresDr Ruberg is supported by NIH grant R01HL139671; has received institutional research grant support from Akcea/Ionis Therapeutics, Anumana, Alnylam Pharmaceuticals, and Pfizer; and has received consulting fees from AstraZeneca and Attralus. All other authors have reported that they have no relationships relevant to the contents of this paper to
-
The Pathogenetic Link Between Ozone Pollution and Cardiovascular Disease J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-22 Alexandra Schneider, Kai Chen, Susanne Breitner
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Associations of Short-Term Ozone Exposure With Hypoxia and Arterial Stiffness J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-22 Qiaoyi Hua, Xin Meng, Wu Chen, Yifan Xu, Ruiwei Xu, Yunxiu Shi, Jiajianghui Li, Xueling Meng, Ailin Li, Qianqian Chai, Mengshuang Sheng, Yuan Yao, Yunfei Fan, Ruohong Qiao, Yi Zhang, Teng Wang, Yidan Zhang, Xiaoyu Cui, Yaqi Yu, Haonan Li, Tong Zhu
-
Worsening of Heart Failure in Outpatients With Transthyretin Amyloidosis and Cardiomyopathy in the APOLLO-B Trial J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-22 Marianna Fontana, Mathew S. Maurer, Julian D. Gillmore, Shaun Bender, Patrick Y. Jay, Scott D. Solomon
-
Wildfires, Compound Extreme Events, Climate Change, and Cardiovascular Health J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-21 Kai Chen, Yuan Lu, Harlan M. Krumholz
No Abstract
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20
Section snippets Tricuspid Valve Interventions: A New Era in Cardiovascular Innovation203Harlan M. Krumholz Quality of Life After Transcatheter Tricuspid Valve Replacement: 1-Year Results From TRISCEND II Pivotal Trial 206Suzanne V. Arnold, Rebecca T. Hahn, Vinod H. Thourani, Raj Makkar, Moody Makar, Rahul P. Sharma, Christiane Haeffele, Charles J. Davidson, Akhil Narang, Brian O’Neill, James Lee,
-
Tricuspid Valve Interventions: A New Era in Cardiovascular Innovation J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Harlan M. Krumholz
Section snippets A New Frontier in Structural Heart DiseaseThe articles featured in this issue emphasize the significant strides made in understanding and treating TR. Once considered a secondary concern, severe TR is now recognized as a condition with profound impacts on quality of life, functional capacity, and clinical outcomes. This shift has been driven by innovations in transcatheter technologies
-
Symptomatic Improvement “Only” in Unblinded Trials: The Plot Thickens J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Alexander M. Levy, Jarmanjeet Singh, Gregg W. Stone
Section snippets Funding Support and Author DisclosuresDr Stone has received speaker honoraria from Medtronic, Amgen, Boehringer Ingelheim, and Abiomed; has served as a consultant to Cardiomech, Robocath, Daiichi-Sankyo, Vectorious, Miracor, Apollo Therapeutics, Cardiac Success, Occlutech, Millennia Biopharma, Remote Cardiac Enablement, Ablative Solutions, Abbott, Valfix, Zoll, HeartFlow, Shockwave
-
The Amara Yad Project: A New Resource for Cardiac Anatomy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Kalyanam Shivkumar, Harlan M. Krumholz
Section snippets The Amara Yad Project: Honoring Victims Through ActionThe Amara Yad Project is a physician-led initiative with a singular mission: to honor the victims of medical exploitation by creating ethical and accessible anatomical resources. Its name combines the Sanskrit word Amara (immortal) and the Hebrew word Yad (hand), symbolizing a commitment to remembrance and purpose. This initiative
-
Amara Yad Image: The Tricuspid Valve J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Kalyanam Shivkumar
Section snippets Funding Support and Author DisclosuresThis work was supported by National Institutes of Health grants OT2OD023848 and P01 HL164311 to Dr Shivkumar and the UCLA Amara-Yad Project. Dr Shivkumar is a consultant to Nference and Anumana.
-
Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Dawei Lin, Xiaochun Zhang, Wenzhi Pan, Daxin Zhou
No Abstract
-
Reply: Characteristics of the Population Undergoing Tricuspid Transcatheter Edge-to-Edge Repair in a Real-World Study J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Karl-Philipp Rommel, Philipp Lurz
No Abstract
-
Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Kartik Giri, Aman Kakkar, Daniel Tarditi, Arthur C. Lee, Maulik Shah
No Abstract
-
Reply: Our Perspective on How Private Equity Platforms Can Accelerate Efforts to Improve Quality and Value J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Victoria L. Bartlett, Michael Liu, Rishi K. Wadhera
No Abstract
-
Where the Definition of Fragility Came From and Where It Will Go? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Ruiting Jia, Yan Zhao, Aisong Zhu
No Abstract
-
Reply: Where the Definition of Fragility Came From and Where It Will Go J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-20 Mario Enrico Canonico, Rupert Bauersachs, Marc P. Bonaca
No Abstract
-
Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-analysis of Randomized Trials J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-17 Sina Rashedi, Mohammad Keykhaei, Alyssa Sato, Philippe Gabriel Steg, Gregory Piazza, John W. Eikelboom, Renato D. Lopes, Marc P. Bonaca, Satoshi Yasuda, Hisao Ogawa, Satoshi Shizuta, Takeshi Kimura, Yasuo Okumura, Felicita Andreotti, Laurent Bertoletti, Gregg W. Stone, Roxana Mehran, David J. Cohen, Gregory Y.H. Lip, Behnood Bikdeli
BackgroundThe optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes. ObjectivesWe aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation
-
The DanGer of Using Age to Decide About Using Microaxial Flow Pumps in Cardiogenic Shock J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-15 Marc D. Samsky, Bernard S. Kadosh, Michael G. Nanna, Sunil V. Rao
Section snippets Funding Support and Author DisclosuresThe authors have reported that they have no relationships relevant to the contents of this paper to disclose.
-
Renal Denervation: Antihypertensive Therapy or Gizmo Idolatry? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-15 Franz H. Messerli
Section snippets Antihypertensive Drug TherapyThe more bromidic a medical issue, the easier it will be hijacked by a high-tech approach whenever the opportunity presents itself. As such, run-of-the-mill antihypertensive therapy can be considered as an ideal target: Ever since the National Heart, Lung, and Blood Institute advocated the stepped-care approach, antihypertensive therapy has lost its highbrow
-
-
Contents J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-13
Section snippets A Comprehensive Exploration of FINEARTS-HF: A JACC Theme Issue103Harlan M. Krumholz, Theresa McDonagh Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial 106Akshay S. Desai, Muthiah Vaduganathan, Brian L. Claggett, Ian J. Kulac, Pardeep S. Jhund, Jonathan Cunningham, Maria Borentain, James Lay-Flurrie, Prabhakar Viswanathan, Katja Rohwedder, Flaviana
-
A Comprehensive Exploration of FINEARTS-HF: A JACC Theme Issue J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-13 Harlan M. Krumholz, Theresa McDonagh
Section snippets The FINEARTS-HF TrialThe FINEARTS-HF trial explored the efficacy and safety of finerenone in patients with HFmrEF/HFpEF, marking a milestone in heart failure research.1 As the first mineralocorticoid receptor antagonist to meet its primary endpoint in this population, finerenone significantly reduced the composite outcome of worsening heart failure events and cardiovascular death.
-
Unentangling Heart Failure From Kidney Outcomes With Finerenone: Insights From the FINEARTS-HF Trial J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-13 Sanjay Kaul, Swapnil Hiremath
Section snippets Funding Support and Author DisclosuresDr Kaul is a consultant to Abbott, Amgen, Bayer, Edwards, Medtronic, ReCor, and Novo Nordisk. Dr Hiremath has received research salary support from the Department of Medicine, University of Ottawa; and serves on the board of NephJC, a 503c organization that supports social media in medical education.
-
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-13 Shingo Matsumoto, Pardeep S. Jhund, Alasdair D. Henderson, Johann Bauersachs, Brian L. Claggett, Akshay S. Desai, Meike Brinker, Patrick Schloemer, Prabhakar Viswanathan, Jon W. Mares, Andrea Scalise, Carolyn S.P. Lam, Gerard C.M. Linssen, Jose Francisco Kerr Saraiva, Michele Senni, Richard Troughton, Jacob A. Udell, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, John J.V. McMurray
-
When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2025-01-13 Kevin Damman
Section snippets Funding Support and Author DisclosuresDr Damman reports speaker/consultancy fees to his institution from Abbott, Boehringer Ingelheim, AstraZeneca, FIRE1, Echosense, and Novartis.